HOME » About Us » Leadership Team » Management Team

    Management Team

     

    Venkateswarlu (Venkat) Nelabhotla, President & Chief Executive Officer & Board Member

    Venkat brings a very rich and global experience of more than 25 years, successfully leading organizations in the biotech and cosmeceutics businesses. He held top management roles in biotech and pharmaceutical companies like ShanthaBiotechnics (A Sanofi Company) and Aurobindo Pharma, roles in which he immensely contributed to the Companies' all-round growth. He was instrumental in creating market focus and orchestrating vaccine portfolio strategy in Shantha Biotech, a biosimilar and vaccine company, which was eventually acquired by Sanofi for $800 million. He has been a part of significant revenue growth and value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.

    He has held CEO and President roles in Emami and Cavinkare, cosmeceutical and consumer product companies in India with global operations, creating value and growing them significantly with an all-rounded approach. During his time at Emami (a publicly listed company) as CEO, the company's market cap increased from $ 300 million to $ 1.2 billion. During the early part of his career, he created some very successful cosmeceutical brands in Cavinkare, and built the organization with a 10x revenue increase in 6 years' time.

    He comes with core strengths in Strategy, Innovation, Technology, Commercialization, Organization building, Finance, M&A. Venkat has received his B.Tech in Mechanical Engineering and an MBA from Indian Institute of Management - Ahmedabad, India.

    Contact information: nvenkat@vyometx.com

     

    Dr. Shiladitya Sengupta, Co-Founder

    Dr. Shiladitya Sengupta is an assistant professor of medicine at Harvard Medical School. He is also the Co-Founder of Invictus Oncology, Cerulean Pharmaceuticals and Mitra Biotech. Shiladitya's research focuses on the development of novel nanomedicines for cancer and angiogenesis-based diseases. In 2005, he was recognized as one of the top 35 innovators worldwide by MIT Technology Review magazine. He has also received the Shakuntala Amir Chand Award from the Indian Council for Medical Research.

    Shiladitya is an alumnus of the All India Institute of Medical Sciences, and completed his PhD as a Nehru Scholar from Trinity College at Cambridge University and was a Fellow at MIT before joining Harvard. He has published over 35 papers, including in Nature and Proceedings of the National Academy of Sciences.

     

    Dr. Charles G. Chavdarian, Ph.D.Senior Vice President, Product Development and Regulatory CMC

    Dr. Charles G. Chavdarian is an industry consultant specializing in Pharmaceutical Research & Development, Analytical R&D, Formulation/Manufacturing, QA/QC, and Regulatory CMC.  He was formerly the Executive Director of Analytical Sciences & Regulatory CMC at Dow Pharmaceutical Sciences, Inc., Petaluma, California.  He held earlier management positions at Syntex Corp., Penederm Inc., ALZA Corp., Cellegy Pharmaceuticals, and InSite Vision.  He has worked in the pharmaceutical industry for over 30 years, and earlier in the chemical industry.  His pharmaceutical expertise spans nearly every dosage form including solid oral, parenteral, topical (dermatological and ophthalmic), and transdermal, and also includes commercial Rx, OTC, and personal care products.  Dr. Chavdarian received his B.S. degree in Chemistry from the University of Michigan, Ann Arbor, and his Ph.D. degree in Organic Chemistry from the University of California, Berkeley, followed by a postdoctoral appointment in Pharmaceutical Chemistry at the University of California, San Francisco Medical Center.  He is the author of over 35 technical publications and patents. His strong technical background includes organic and analytical chemistry, analytical method development and validation, formulation development and manufacturing support (APIs and drug products), technology transfer, bioanalytical studies, quality control testing, stability testing, management of stability facilities and studies, and QA auditing of GMP laboratories and manufacturing facilities.  He has also worked as a project manager and as a business development representative with client companies, and has performed due diligence audits/inspections.  Dr. Chavdarian has extensive experience with regulatory CMC where he has led technical teams involved in the design and implementation of Phase 1 through 4 stability programs, and the compilation and authorship of drug substance and drug product CMC sections for regulatory submissions (i.e., e-CTDs), both domestically and internationally (IND, NDA, ANDA, NDS, CTA, IMPD, MAA). In addition, Dr. Chavdarian has interacted first-hand with regulatory agencies (FDA, Health Canada, Europe) on many occasions (pre-Phase 1 and Phase1 – Phase 3 Guidance meetings, Pre-Approval Inspections), and has successfully worked on many approved drug applications – e.g., NDA, NDS, and ANDA submissions.  Dr. Chavdarian has been a speaker at several technical workshops and conferences, including a national webinar on topical drug product development.
     

    Dr. Rena Patel, Chief Patent Counsel

    Dr. Rena Patel is a seasoned IP attorney and has been in practice since 1998. She is a graduate of Duquesne University (Ph.D.) and California Western School of Law (J.D.). She started her law career as an associate at Woodcock Washburn (now Baker Hostetler), progressing to Patent Counsel at Bristol-Myers Squibb Company, and Chief Patent Counsel – Oral Care at Colgate-Palmolive Company.

    Rena has significant global experience in IP practice having also been an independent consultant working with start-up ventures and multinational pharmaceutical companies in Europe and Asia. Rena has a strong interest in education and serves as the vice-president of the West Windsor-Plainsboro Education Foundation, which is a private, non-profit organization that supports excellence in the WW-P Regional Schools through innovative programs, strategic initiatives, and funding of grants for teachers.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.